Basser Professor of Medicine, University Pennsylvania
Oncology
Dr. Susan M. Domchek, MD
|
|
Give Review
Susan M. Domchek, MD is an expert in the field of Oncology. She attended Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. She over the years received 5 awards: "America's Top Doctors", "Philadelphia Magazine", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Dr. Susan M. Domchek is a published doctor as well. She has 81 publications published. The latest was: Utilizing Remote Real-Time Videoconferencing to Expand Access to Cancer Genetic Services in Community Practices: A Multicenter Feasibility Study. She accepts Medicare payments and is listed with Medicare.gov.
Publications
- BRIP1 as an ovarian Cancer susceptibility gene: ready for the clinic?
- American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.
- Dose-response effects of aerobic exercise on estrogen among women at high risk for breast Cancer: a randomized controlled trial.
- RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction.
- Women In Steady Exercise Research (WISER) Sister: Study design and methods.
- Breast MRI FibroGlandular Volume and Parenchymal Enhancement in BRCA1 and BRCA2 Mutation Carriers Before and Immediately After Risk-Reducing Salpingo-Oophorectomy.
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety and Predictive Biomarker Assessment.
- Prevalence of mutations in a panel of breast Cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast Cancer.
- Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for Cancer susceptibility.
- Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
- Panel testing for inherited susceptibility to breast, ovarian, and colorectal Cancer.
- Multiplex genetic testing: reconsidering utility and informed consent in the era of next-generation sequencing.
- Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: Systematic Review and Meta-Analysis.
- Long-term risk of medical conditions associated with breast Cancer treatment.
- Contraceptive use and the role of contraceptive counseling in reproductive-aged women with Cancer.
- Are physician recommendations for BRCA1/2 testing in patients with breast Cancer appropriate? A population-based study.
- Agreement of self-reported hormone receptor status with Cancer registry data in young breast Cancer patients.
- Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk.
- Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk.
- Fine-mapping of Breast Cancer Genome-wide Association Studies Loci in Women of African Ancestry Identifies Novel Susceptibility Markers.
- Incremental impact of breast Cancer SNP panel on risk classification in a screening population of white and African American women.
- Multiplex Genetic Testing for Cancer Susceptibility: Out on the High Wire Without a Net?
- Melanoma Genetic Testing, Counseling, and Adherence to Skin Cancer Prevention and Detection Behaviors.
- A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.
- A genome-wide association study of breast Cancer in women of African ancestry.
- Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer.
- Risk of metachronous breast Cancer after BRCA mutation-associated ovarian Cancer.
- Breast reconstruction in bilateral prophylactic mastectomy patients: Factors that influence decision making.
- Understanding participation by African Americans in Cancer genetics research.
- Cancer treatment according to BRCA1 and BRCA2 mutations.
- How Genetic Variant Libraries Effectively Extend Gene Testing Patents: Implications for Intellectual Property and Good Clinical Care.
- Low Rates of African American Participation in Genetic Counseling and Testing for BRCA1/2 Mutations: Racial Disparities or Just a Difference?
- CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients.
- Breast and Ovarian Cancer Risk and Risk Reduction in Jewish BRCA1/2 Mutation Carriers.
- Genetic Susceptibility to Type 2 Diabetes and Breast Cancer Risk in Women of European and African Ancestry.
- Follow-up Frequency and Compliance in Women with Probably Benign Findings on Breast Magnetic Resonance Imaging.
- Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast Cancer in women of African ancestry.
- Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From BRCA1/2-Associated Breast Cancer.
- Exercise Lowers Estrogen and Progesterone Levels in Premenopausal Women at High Risk of Breast Cancer.
- The tubal hypothesis of ovarian Cancer: caution needed.
- Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1 Interacting Genes.
- Clinically relevant changes in family history of Cancer over time.
- Genetic Variation in IGF2, HTRA1, and MMP3 and Breast Cancer Risk Among BRCA1 and BRCA2 Carriers.
- Exploring the link between MORF4L1 and risk of breast Cancer.
- Clinical management of hereditary breast Cancer syndromes.
- PALB2 mutations in familial breast and pancreatic Cancer.
- Therapeutic approaches for women predisposed to breast Cancer.
- Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's Lymphoma.
- Breast Cancer in young women.
- Breast Cancer predisposition syndromes.
- Preventive surgery is associated with reduced Cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
- Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with Cancer risk and mortality.
- Tremelimumab in combination with exemestane in patients with advanced breast Cancer and treatment-associated modulation of inducible costimulator expression on patient...
- Breast Cancer gene variants: separating the harmful from the harmless.
- Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del.
- Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other Cancers.
- Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
- Clinical implications of low-penetrance breast Cancer susceptibility alleles.
- Proceedings of the international consensus conference on breast Cancer risk, genetics, & risk management, April, 2007.
- The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast Cancer families.
- Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic Cancer: a multicenter, prospective study.
- Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations.
- The clinical management of BRCA1 and BRCA2 mutation carriers.
- Differential lysis of tumors by polyclonal T cell lines and T cell clones specific for hTERT.
- Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
- Telomerase-specific T-cell immunity in breast Cancer: effect of vaccination on tumor immunosurveillance.
- Cancer risk models: translating family history into clinical management.
- The prevention of hereditary breast Cancer.
- Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast Cancer screening study.
- Childhood Cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast Cancer clinic.
- Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers.
- Knowledge, attitudes, and utilization of BRCA1/2 testing among women with early-onset breast Cancer.
- Vaccination of Cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.
- Central Nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
- Application of breast Cancer risk prediction models in clinical practice.
- Recent advances in breast Cancer biology.
- Lymphomas of the Breast: primary and secondary involvement.
- Utilizing Remote Real-Time Videoconferencing to Expand Access to Cancer Genetic Services in Community Practices: A Multicenter Feasibility Study.
- DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.
- Associations between breast density and a panel of single nucleotide polymorphisms linked to breast Cancer risk: a cohort study with digital mammography.
Schools
Harvard Medical School
Massachusetts General Hospital
Dana FarberPtnrs
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Philadelphia Magazine
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
Massachusetts General Hospital -
Harvard Medical School
Hospital
-
Hospital of the University of Pennsylvania
Drug Facts
| NPI NUMBER | 1487695102 | |
| NPPES Provider LastName | DOMCHEK | |
| NPPES Provider FirstName | SUSAN | |
| NPPES Provider ZIPCode | 19104 | |
| NPPES Provider State | PA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 125.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1487695102 |
| Last Name Of The Provider | DOMCHEK |
| First Name Of The Provider | SUSAN |
| View All |
Similar Doctors
|
|
Dr. Adam D. Cohen, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lainie Martin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marijo Bilusic, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jianqing Lin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Diane M. Hershock, MD |
|
|
Dr. Naomi S. Haas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jared M. Weiss, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ursina R. Teitelbaum, MD
This Doctor is OpenDoctor Recommended.
|